PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

20141,054 citationsJournal Articlebronze Open Access

Authors

Ajay K. Gopal · Cancer Research Center

Brad S. Kahl · University of Wisconsin Carbone Cancer Center

Sven de Vos · University of California, Los Angeles

Nina D. Wagner‐Johnston · Washington University in St. Louis

Stephen J. Schuster · University of Pennsylvania

Wojciech Jurczak · Jagiellonian University

Ian W. Flinn

Abstract

In this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov number, NCT01282424.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Immune Cell Function and Interaction

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 11, pp. 1008-1018

DOI: 10.1056/nejmoa1314583

Field-Weighted Citation Impact: 70.47